PL3055333T4 - Wykorzystanie inhibitora pcsk9 do leczenia hyperlipidemii - Google Patents

Wykorzystanie inhibitora pcsk9 do leczenia hyperlipidemii

Info

Publication number: PL3055333T4
Authority: PL; Poland
Prior art keywords: pcsk9 inhibitor; treat hyperlipidemia; hyperlipidemia; treat; pcsk9
Prior art date: 2013-10-11

Application number

PL14802527T

Other languages

English (en)

Other versions

PL3055333T3 (pl

Inventor

Marie BACCARA-DINET

Laurence BESSAC

Umesh CHAUDHARI

Corinne Hanotin

Robert C. Pordy

William J. Sasiela

Daniel A. Schwemmer Gipe

Original Assignee

Sanofi Biotechnology

Regeneron Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-10-11

Filing date

2014-10-10

Publication date

2020-07-27

2014-10-10 Application filed by Sanofi Biotechnology, Regeneron Pharmaceuticals, Inc. filed Critical Sanofi Biotechnology

2020-06-01 Publication of PL3055333T3 publication Critical patent/PL3055333T3/pl

2020-07-27 Publication of PL3055333T4 publication Critical patent/PL3055333T4/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Mycology (AREA)
Microbiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Emergency Medicine (AREA)

PL14802527T 2013-10-11 2014-10-10 Wykorzystanie inhibitora pcsk9 do leczenia hyperlipidemii PL3055333T4 (pl)

Applications Claiming Priority (10)

Application Number	Priority Date	Filing Date	Title
US201361890154P	2013-10-11	2013-10-11
US201461923103P	2014-01-02	2014-01-02
US201461955514P	2014-03-19	2014-03-19
US201462004620P	2014-05-29	2014-05-29
US201462025104P	2014-07-16	2014-07-16
EP14306221		2014-07-31
US201462054571P	2014-09-24	2014-09-24
EP14306584		2014-10-09
PCT/US2014/060109 WO2015054619A2 (en)	2013-10-11	2014-10-10	Use of a pcsk9 inhibitor to treat hyperlipidemia
EP14802527.3A EP3055333B1 (en)	2013-10-11	2014-10-10	Use of a pcsk9 inhibitor to treat hyperlipidemia

Publications (2)

Publication Number	Publication Date
PL3055333T3 PL3055333T3 (pl)	2020-06-01
PL3055333T4 true PL3055333T4 (pl)	2020-07-27

Family

ID=52813751

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL19210918T PL3689913T3 (pl)	2013-10-11	2014-10-10	Zastosowanie inhibitora PCSK9 do leczenia hiperlipidemii
PL14802527T PL3055333T4 (pl)	2013-10-11	2014-10-10	Wykorzystanie inhibitora pcsk9 do leczenia hyperlipidemii

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL19210918T PL3689913T3 (pl)	2013-10-11	2014-10-10	Zastosowanie inhibitora PCSK9 do leczenia hiperlipidemii

Country Status (14)

Country	Link
US (1)	US20150140002A1 (pl)
EP (2)	EP3055333B1 (pl)
JP (2)	JP6846931B2 (pl)
KR (3)	KR20160062166A (pl)
CN (3)	CN115154599A (pl)
AU (2)	AU2014331754B2 (pl)
CA (1)	CA2926942A1 (pl)
EA (1)	EA037526B1 (pl)
ES (1)	ES2914978T3 (pl)
IL (1)	IL244995B (pl)
MX (3)	MX373298B (pl)
PL (2)	PL3689913T3 (pl)
TW (1)	TWI669131B (pl)
WO (1)	WO2015054619A2 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130064834A1 (en)	2008-12-15	2013-03-14	Regeneron Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar)	2008-12-15	2020-08-27	Regeneron Pharma	أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN110711248A (zh)	2011-01-28	2020-01-21	赛诺菲生物技术公司	包含针对pcsk9的人抗体的药物组合物
AR087305A1 (es)	2011-07-28	2014-03-12	Regeneron Pharma	Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2992345T3 (es)	2011-09-16	2024-12-11	Regeneron Pharma	Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
US9255154B2 (en)	2012-05-08	2016-02-09	Alderbio Holdings, Llc	Anti-PCSK9 antibodies and use thereof
US10058630B2 (en) *	2012-10-22	2018-08-28	Concievalve, Llc	Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10111953B2 (en)	2013-05-30	2018-10-30	Regeneron Pharmaceuticals, Inc.	Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
AU2014274844B2 (en)	2013-06-07	2019-11-28	Regeneron Pharmaceuticals, Inc.	Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
EP3068803B1 (en)	2013-11-12	2021-01-20	Sanofi Biotechnology	Dosing regimens for use with pcsk9 inhibitors
US20170198059A1 (en) *	2014-07-14	2017-07-13	Amgen Inc.	Crystalline antibody formulations
RU2735521C2 (ru)	2014-07-16	2020-11-03	Санофи Байотекнолоджи	Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh)
JP2018516624A (ja) *	2015-04-15	2018-06-28	コンシーヴァルブエルエルシー	自然心臓弁、ステント装着された心臓弁またはバイオプロテーゼの狭窄、閉塞または石灰化を抑制するためのデバイスおよび方法
CN104861071B (zh) *	2015-04-27	2019-04-12	南京师范大学	针对pcsk9的全人源单克隆抗体的可变区基因及其应用
US10772956B2 (en)	2015-08-18	2020-09-15	Regeneron Pharmaceuticals, Inc.	Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
WO2018054241A1 (en)	2016-09-20	2018-03-29	Wuxi Biologics (Shanghai) Co., Ltd.	Novel anti-pcsk9 antibodies
EP3609532A1 (en)	2017-04-13	2020-02-19	Cadila Healthcare Limited	Novel peptide based pcsk9 vaccine
US20200131576A1 (en)	2017-04-25	2020-04-30	The Brigham And Women's Hospital, Inc.	IL-8, IL-6, IL-1 Beta and TET2 and DNMT3A in Atherosclerosis
CN107090474A (zh) *	2017-05-22	2017-08-25	山东大学	一种腹主动脉瘤疾病动物模型的制备方法
WO2018228406A1 (zh) *	2017-06-14	2018-12-20	江苏恒瑞医药股份有限公司	Pcsk9抗体、其抗原结合片段及其医药用途
CN113015543A (zh) *	2018-03-06	2021-06-22	赛诺菲生物技术公司	Pcsk9抑制剂用于降低心血管风险的用途
JOP20190150A1 (ar)	2018-06-21	2019-12-21	Merck Sharp & Dohme	مركبات مناهضة لـ pcsk9
EP4470609A3 (en)	2019-01-18	2025-03-12	Astrazeneca AB	Pcsk9 inhibitors and methods of use thereof
IL323016A (en) *	2019-11-18	2025-10-01	Ad Pharmaceuticals Co Ltd	Anti-pcsk9 antibody and its use
CA3161347A1 (en) *	2019-12-10	2021-06-17	Shazia ALI	Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia
CN114277032A (zh) *	2021-12-31	2022-04-05	华中科技大学同济医学院附属协和医院	一种低密度脂蛋白受体基因突变体及其应用
CN116983434B (zh) *	2023-09-28	2024-03-15	康霖生物科技（杭州）有限公司	用于基因治疗的核酸构建体及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
US8357371B2 (en) *	2008-12-15	2013-01-22	Regeneron Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia using antibodies to PCSK9
US20130064834A1 (en) *	2008-12-15	2013-03-14	Regeneron Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar)	2008-12-15	2020-08-27	Regeneron Pharma	أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN110711248A (zh) *	2011-01-28	2020-01-21	赛诺菲生物技术公司	包含针对pcsk9的人抗体的药物组合物
JOP20200043A1 (ar) *	2011-05-10	2017-06-16	Amgen Inc	طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20130006482A1 (en) *	2011-06-30	2013-01-03	Ramadev Burigsay Hukkeri	Guidance system for a mobile machine
AR087305A1 (es)	2011-07-28	2014-03-12	Regeneron Pharma	Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2992345T3 (es) *	2011-09-16	2024-12-11	Regeneron Pharma	Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
TWI682780B (zh) *	2013-05-30	2020-01-21	美商再生元醫藥公司	醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途

2014
- 2014-10-10 CA CA2926942A patent/CA2926942A1/en active Pending
- 2014-10-10 KR KR1020167012099A patent/KR20160062166A/ko not_active Ceased
- 2014-10-10 EP EP14802527.3A patent/EP3055333B1/en active Active
- 2014-10-10 JP JP2016521604A patent/JP6846931B2/ja active Active
- 2014-10-10 PL PL19210918T patent/PL3689913T3/pl unknown
- 2014-10-10 CN CN202210729601.0A patent/CN115154599A/zh active Pending
- 2014-10-10 AU AU2014331754A patent/AU2014331754B2/en active Active
- 2014-10-10 ES ES19210918T patent/ES2914978T3/es active Active
- 2014-10-10 EA EA201690754A patent/EA037526B1/ru unknown
- 2014-10-10 MX MX2016004580A patent/MX373298B/es active IP Right Grant
- 2014-10-10 CN CN202210762455.1A patent/CN115192704A/zh active Pending
- 2014-10-10 PL PL14802527T patent/PL3055333T4/pl unknown
- 2014-10-10 KR KR1020227011822A patent/KR20220048051A/ko not_active Ceased
- 2014-10-10 CN CN201480066894.2A patent/CN105814085A/zh active Pending
- 2014-10-10 EP EP19210918.9A patent/EP3689913B1/en active Active
- 2014-10-10 US US14/511,975 patent/US20150140002A1/en not_active Abandoned
- 2014-10-10 KR KR1020237026483A patent/KR20230119045A/ko not_active Ceased
- 2014-10-10 WO PCT/US2014/060109 patent/WO2015054619A2/en not_active Ceased
- 2014-10-13 TW TW103135495A patent/TWI669131B/zh active
2016
- 2016-04-08 MX MX2020004023A patent/MX2020004023A/es unknown
- 2016-04-08 MX MX2022013172A patent/MX2022013172A/es unknown
- 2016-04-10 IL IL244995A patent/IL244995B/en active IP Right Grant
2019
- 2019-08-09 JP JP2019146940A patent/JP6994484B2/ja active Active
2020
- 2020-06-02 AU AU2020203636A patent/AU2020203636B2/en active Active

Also Published As

Publication number	Publication date
EP3055333B1 (en)	2019-12-04
AU2020203636A1 (en)	2020-06-25
US20150140002A1 (en)	2015-05-21
AU2020203636B2 (en)	2023-05-18
KR20160062166A (ko)	2016-06-01
TWI669131B (zh)	2019-08-21
EP3689913B1 (en)	2022-03-23
EA037526B1 (ru)	2021-04-08
CN105814085A (zh)	2016-07-27
MX2016004580A (es)	2016-12-08
EA201690754A1 (ru)	2016-10-31
IL244995B (en)	2019-12-31
AU2014331754A1 (en)	2016-05-26
PL3689913T3 (pl)	2022-07-04
MX2020004023A (es)	2020-08-13
WO2015054619A8 (en)	2016-03-31
IL244995A0 (en)	2016-05-31
PL3055333T3 (pl)	2020-06-01
MX2022013172A (es)	2022-11-30
WO2015054619A3 (en)	2015-06-04
CA2926942A1 (en)	2015-04-16
KR20230119045A (ko)	2023-08-14
JP6994484B2 (ja)	2022-02-04
EP3055333A2 (en)	2016-08-17
JP2019214594A (ja)	2019-12-19
CN115192704A (zh)	2022-10-18
MX373298B (es)	2020-05-20
JP6846931B2 (ja)	2021-03-24
AU2014331754B2 (en)	2020-06-18
KR20220048051A (ko)	2022-04-19
EP3689913A1 (en)	2020-08-05
JP2016538248A (ja)	2016-12-08
WO2015054619A2 (en)	2015-04-16
ES2914978T3 (es)	2022-06-20
TW201605475A (zh)	2016-02-16
CN115154599A (zh)	2022-10-11

Publication	Publication Date	Title
IL244995A0 (en)	2016-05-31	Using pcsk9 inhibitor to treat hyperlipidemia
IL279682A (en)	2021-03-01	Benzoquinolone compounds as VMAT2 inhibitors
PL3080100T3 (pl)	2023-03-06	Inhibitory lizyno-specyficznej demetylazy-1
EP2948450A4 (en)	2016-11-09	METALLOENZYMINHIBITORVERBINDUNGEN
ZA201702252B (en)	2019-06-26	A selective inhibitor of prosphatidylinositol 3-kinase-gamma
PT3293176T (pt)	2021-03-03	Forma cristalina de um inibidor de pde4
DK2928477T3 (da)	2019-10-07	Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis
EP2958964A4 (en)	2016-08-10	TREATMENT OF FREQUENTLY AFFECTED SURFACES TO IMPROVE HYGIENE
EP2962186A4 (en)	2016-10-12	PROVISION OF CODE CHANGE JOB PACKAGES OF VARIOUS SIZE FOR VALIDATORS
ZA201409181B (en)	2015-12-23	Treatment of waste water
ZA202207530B (en)	2023-10-25	Use of phenoxypropylamine compounds to treat depression
IL244617A0 (en)	2016-04-21	Benzoquinolone compounds as vmat2 inhibitors
IL240763B (en)	2019-11-28	The halopyrazoles as thrombin inhibitors
PL2888228T3 (pl)	2019-10-31	Inhibitory oddziaływania CD40-TRAF6
PT3055333T (pt)	2020-03-11	Uso de um inibidor de pcsk9 para tratar a hiperlipidemia
PT3689913T (pt)	2022-06-20	Uso de um inibidor de pcsk9 para tratar a hiperlipidemia
ZA201409002B (en)	2015-12-23	Treatment of waste water
GB201308117D0 (en)	2013-06-12	Inhibitor of calcifying disorders
GB201322036D0 (en)	2014-01-29	New therapeutic uses of enzyme inhibitors
GB201310488D0 (en)	2013-07-24	New therapeutic uses of enzyme inhibitors